Navigation Links
Phosphagenics Announces Completion of Transdermal Patch Prototypes
Date:5/29/2009

d by Phosphagenics have demonstrated that its patented technology can deliver opiates through the skin without causing any skin damage or irritation. Incorporating this technology into a patch will enable a more convenient and effective treatment that is capable of meeting the needs of pain sufferers and addresses the concerns of regulatory authorities regarding potential abuse.

In this most recent preclinical study, oxycodone concentrations produced by the patch reached approximately 160ng/ml and remained significantly elevated (p<0.01) and within therapeutic range for the duration of the four hour study. In contrast, the TPM/oxycodone gel produced peak plasma oxycodone concentrations of approximately 80ng/ml 30 minutes after application and declined from that point over the course of the trial.

"The development of our TPM patch has the potential to be a substantial commercial success for Phosphagenics," said Dr. Ogru. "Our transdermal patch should increase the amount and duration of oxycodone delivered into the systemic circulation, and could reduce potential opioid abuse, a major consideration for the FDA when reviewing possibly addictive substances such as oxycodone. In addition, our TPM skin patch should allow us to deliver other opioid based compounds, including morphine and hydromorphone, as well as other products that are targeted for delivery into the systemic circulation, including insulin. Phosphagenics has already completed a human trial that demonstrated that its TPM/insulin formulation safely delivered insulin transdermally into patients with Type 1 diabetes."

APPENDIX AND NOTES TO EDITORS

About Phosphagenics Limited

Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical produc
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
2. Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results
3. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
4. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
5. Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better
6. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
7. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
8. Medivation Announces Pricing of Public Offering
9. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. SENOMYX ANNOUNCES APPOINTMENT OF DAVID L. LINEMEYER, PH.D., AS VICE PRESIDENT, BIOLOGY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
(Date:11/21/2014)... 20, 2014 The California ... research organization representing leading California academic institutions, biotechnology, ... PwC US today released a report revealing ... industry growth. The trend shows a 4 percent ... California Biomedical Industry Report indicates that, while ...
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... - Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") ... a brokered private placement offering (the "Brokered Offering") ... Securities Inc. and Clarus Securities Inc. acted as ... syndicate of agents that also included Wolverton Securities ... Concurrently with the Brokered Offering, the Company also ...
Breaking Biology Technology:TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... SAFC Pharma(TM), a focus,area within SAFC(R), a member ... announced that a new reactor at its Arklow ... capacity for large-scale,active pharmaceutical ingredient (API) manufacturing by ... a series of investments designed to,enhance production capacity ...
... JOSE, Calif., Sept. 26 Dr. Qi Lu, former EVP ... and serve as the president of HYSTA, USA. HYSTA is ... officially left Yahoo! at end of August, he had served ... both personally and professionally,but one thing that has not changed ...
... PIP ), a biodefense company developing medical ... the National,Institute of Allergy and Infectious Diseases (NIAID), ... awarded the Company a multi-year contract,for up to ... generation,recombinant protective antigen (rPA) anthrax vaccine., The ...
Cached Biology Technology:SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland 2SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland 3Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA 2PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 2PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 3PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 4PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 5PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program 6
(Date:11/21/2014)... SAN JOSE, Calif. , Nov. 20, 2014 /PRNewswire/ ... a global leader in microcontroller (MCU) and touch technology ... digital temperature sensors with the widest V ... family delivers higher temperature accuracy and faster I 2 ... nonvolatile registers and serial EEPROM memory making them ideal ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3Study finds laundry detergent pods, serious poisoning risk for children 2
... 12, 2009) German scientist Otto H. Warburg,s theory ... Prize in 1931, but the biochemical basis for his ... from irreversible injury to cellular respiration eventually fell out ... the cause of uncontrolled cell growth. Seventy-eight years ...
... Fla. A Mayo Clinic-led international consortium has ... and other neurological disorders. Studying just ... have discovered a genetic defect that results in ... as Perry syndrome. Although this syndrome is exceedingly ...
... 12 Industry Leaders Chosen for BOSS-UROCKVILLE, Md., Jan. 8 ... named Lockheed Martin (NYSE: LMT ) an industry ... Operations and Support Services - Unrestricted (BOSS-U) vehicle. As ... selected to participate in this indefinite delivery, indefinite quantity (ID/IQ) ...
Cached Biology News:Nearly a century later, new findings support Warburg theory of cancer 2Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 2Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 3Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases 4Lockheed Martin Team Wins Role on Key Department of Defense Biometrics Contract Vehicle 2
... weight determinations for petroleum-based applications. Multiple solvents can be used, such as water, benzene, formamide, ... ... ... ...
Fast, sensitive quantitation of total MEK 1/2 concentration....
... For the ultimate in utility and ... to meet the needs of the researcher. ... interior dimensions or as sheet material that ... enclosures. These isolators are autoclavable and non-cytotoxic ...
... Automatic High Sensitivity Laboratory Osmometer for 50 L samples. Operating head automatically rises at the end of ... ... ... ...
Biology Products: